Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:IBRX News 29 November 2025 - 18 January 2026

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio shares surged 39.8% to $5.52 Friday after the company projected 2025 ANKTIVA net product revenue of $113 million, up about 700% from last year. The stock rose further to $6.04 in after-hours trading. Trial enrollment for its bladder cancer study reached over 85%, and new CAR-NK data showed a 15-month complete response in Waldenström lymphoma.
18 January 2026
···
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio shares jumped 39.9% to $5.52 Friday after reporting a sharp rise in preliminary 2025 ANKTIVA sales and positive trial updates. The company projected about $113 million in 2025 net product revenue for ANKTIVA, up nearly 700% from 2024. An interim analysis showed higher complete response rates for ANKTIVA plus BCG in bladder cancer. U.S. markets reopen Tuesday after the MLK Jr. holiday.
17 January 2026
···
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares surged 35% Friday after reporting faster enrollment and positive interim results in its ANKTIVA bladder cancer trial. The company also disclosed $113 million in 2025 preliminary revenue and Saudi approval for ANKTIVA in lung cancer. Shares traded at $5.34 by midday with 133 million shares changing hands. Early data from its CD19 CAR-NK cell therapy showed complete responses in Waldenström lymphoma.
16 January 2026
·····
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
····
ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

ImmunityBio shares surged 32% premarket after reporting preliminary 2025 product revenue of $38.3 million for Q4, up 20% from Q3 and 431% year over year. Saudi regulators granted accelerated approval for ANKTIVA in lung and bladder cancer. The company ended the quarter with $242.8 million in cash. Revenue figures are unaudited and may change.
16 January 2026
····
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio shares rose 6.4% to $2.76 Tuesday after reporting new lung cancer trial data for its drug ANKTIVA. The company said ANKTIVA combined with checkpoint inhibitors restored immune-cell levels in two studies, with one showing longer median survival for patients with higher lymphocyte counts. A Phase 3 trial comparing ANKTIVA to docetaxel is ongoing. Fuller results are pending peer review.
13 January 2026
····
ImmunityBio stock today: IBRX slips in premarket as U.S.-Saudi biotech summit nears

ImmunityBio stock today: IBRX slips in premarket as U.S.-Saudi biotech summit nears

New York, Jan 13, 2026, 05:42 (ET) — Premarket ImmunityBio shares were down 0.8% in premarket trading on Tuesday at $2.57, as of 5:00 a.m. ET. Around 13,000 shares had traded by that point, according to Public.com data. Premarket trading runs before the regular U.S. session opens at 9:30 a.m. ET and can be choppy. (Public) The biotech’s latest catalyst is a conference-week push into the spotlight. ImmunityBio and NantWorks on Monday announced an inaugural U.S.-Saudi Biotech Alliance Summit in San Francisco on Jan. 14, alongside the annual J.P. Morgan Healthcare Conference. “This initiative is about moving from strategy to
13 January 2026
···
ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

December 15, 2025 — ImmunityBio, Inc. (NASDAQ: IBRX) is back on investors’ radar today as fresh coverage and new analysis dig into a major European regulatory milestone for its lead therapy ANKTIVA (nogapendekin alfa inbakicept). The market’s obsession is simple: does this become the catalyst that turns ImmunityBio into a real commercial oncology story—or just the latest biotech pop before the harder work of reimbursement, uptake, and cash management begins? Below is a complete, publication-ready roundup of the news, forecasts, and market analysis circulating on December 15, 2025, plus the key fundamentals investors are weighing right now. Why ImmunityBio stock
15 December 2025
···
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

Published: November 29, 2025 ImmunityBio, Inc. (NASDAQ: IBRX) has jumped back onto traders’ and long‑term investors’ radar after a powerful late‑November rally in its share price, driven by blockbuster third‑quarter numbers for its cancer drug Anktiva and a wave of bullish commentary across financial media. On Friday, November 28, ImmunityBio stock closed around the mid‑$2 range after intraday gains of roughly 9–13%, with heavy volume and wide trading ranges highlighted by multiple trader‑focused outlets.Timothy Sykes+2StocksToTrade+2 Yet despite the surge, shares remain down mid‑teens year‑to‑date and far below analysts’ double‑digit price targets. Here’s how the latest news as of November 29,
29 November 2025
···
1 2

Stock Market Today

Go toTop